MX2022013984A - Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7). - Google Patents

Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).

Info

Publication number
MX2022013984A
MX2022013984A MX2022013984A MX2022013984A MX2022013984A MX 2022013984 A MX2022013984 A MX 2022013984A MX 2022013984 A MX2022013984 A MX 2022013984A MX 2022013984 A MX2022013984 A MX 2022013984A MX 2022013984 A MX2022013984 A MX 2022013984A
Authority
MX
Mexico
Prior art keywords
sup
nek7
inhibitors
mitosis
never
Prior art date
Application number
MX2022013984A
Other languages
English (en)
Inventor
David James Bearss
Iii John Sai Keong Kauwe
Alexis Henri Abel Mollard
Original Assignee
Halia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halia Therapeutics Inc filed Critical Halia Therapeutics Inc
Publication of MX2022013984A publication Critical patent/MX2022013984A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan compuestos que tienen actividad como inhibidores de NEK7. Los compuestos tienen la Estructura (I): (ver Fórmula) (I) o una sal, estereoisómero o profármaco farmacéuticamente aceptable de los mismos, caracterizado porque A, X, Y, R1, R2, R3, R 4y R5 son como se definen aquí. También se proporcionan métodos asociados con la preparación y el uso de los compuestos, composiciones farmacéuticas que comprenden los compuestos y métodos para modular la actividad del inflamasoma NLRP3.
MX2022013984A 2020-05-08 2021-05-07 Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7). MX2022013984A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022159P 2020-05-08 2020-05-08
US202163170761P 2021-04-05 2021-04-05
PCT/US2021/031394 WO2021242505A1 (en) 2020-05-08 2021-05-07 Inhibitors of nek7 kinase

Publications (1)

Publication Number Publication Date
MX2022013984A true MX2022013984A (es) 2023-01-30

Family

ID=77774963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013984A MX2022013984A (es) 2020-05-08 2021-05-07 Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).

Country Status (25)

Country Link
US (3) US11161852B1 (es)
EP (1) EP4146348B1 (es)
JP (1) JP7796671B2 (es)
KR (1) KR20230008763A (es)
CN (2) CN120699028A (es)
AU (1) AU2021280893A1 (es)
BR (1) BR112022022669A2 (es)
CA (1) CA3182276A1 (es)
CO (1) CO2022017622A2 (es)
DK (1) DK4146348T3 (es)
ES (1) ES2991366T3 (es)
FI (1) FI4146348T3 (es)
HR (1) HRP20241304T1 (es)
HU (1) HUE068185T2 (es)
IL (1) IL297979A (es)
LT (1) LT4146348T (es)
MX (1) MX2022013984A (es)
PH (1) PH12022553024A1 (es)
PL (1) PL4146348T3 (es)
PT (1) PT4146348T (es)
RS (1) RS65962B1 (es)
SI (1) SI4146348T1 (es)
TW (1) TW202208356A (es)
WO (1) WO2021242505A1 (es)
ZA (1) ZA202212146B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4146348T3 (da) * 2020-05-08 2024-09-30 Halia Therapeutics Inc Inhibitorer af nek7-kinase
CN114751874B (zh) * 2022-05-30 2025-01-24 江南大学 作为TRPV4-KCa2.3促耦联剂的1-苄基-4-乙基哌嗪衍生物及其应用
AU2023334673A1 (en) 2022-08-29 2025-03-27 Japan Tobacco Inc. Pyrazolopyrimidine compound and pharmaceutical use thereof
WO2024059200A1 (en) * 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors
WO2024167423A1 (en) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds
CN121368594A (zh) * 2023-05-26 2026-01-20 哈利亚治疗公司 Nek7抑制剂的多晶型物
WO2025010421A1 (en) * 2023-07-06 2025-01-09 Halia Therapeutics, Inc. Pharmaceutical compositions for inhibitors of nek7 kinase
WO2025067411A1 (zh) * 2023-09-28 2025-04-03 北京普祺医药科技股份有限公司 一种nek7抑制剂、药物组合物及其用途
WO2025140570A1 (zh) * 2023-12-29 2025-07-03 北京普祺医药科技股份有限公司 一种nek7抑制剂、药物组合物及其用途
TW202539650A (zh) * 2024-01-25 2025-10-16 美商哈利亞製藥公司 治療疼痛的方法
WO2025190317A1 (en) * 2024-03-13 2025-09-18 National Institute Of Biological Sciences, Beijing Urea compounds as nlrp3 agonists
CN118812538A (zh) * 2024-06-18 2024-10-22 南京健康产业研究院 一种具有抗肾癌活性的化合物及其制备方法与应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
AU2000240570A1 (en) 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
TWI263640B (en) 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
JP2007512255A (ja) 2003-11-13 2007-05-17 アンビット バイオサイエンシス コーポレーション キナーゼ調節因子としての尿素誘導体
US7947835B2 (en) 2005-03-10 2011-05-24 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
CN101808666A (zh) 2007-07-31 2010-08-18 先灵公司 作为抗癌治疗的抗有丝分裂剂和激光激酶抑制剂组合
PT2947072T (pt) 2008-03-17 2016-12-06 Ambit Biosciences Corp 1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas
EP2348018A4 (en) 2008-09-25 2012-04-25 Kyorin Seiyaku Kk HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR CONTAINING ACTIVE SUBSTANCE
WO2010036631A2 (en) 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
EP2467137A1 (en) 2009-08-19 2012-06-27 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
AU2011239537A1 (en) 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EP2802212B1 (en) 2012-01-12 2015-12-30 Basf Se Herbicidal isoxazolo[5,4-b]pyridines
US9682083B2 (en) 2013-05-14 2017-06-20 Nerviano Medical Sciences S.R.L. Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
AU2014278231B2 (en) 2013-06-11 2017-05-25 KALA BIO, Inc. Urea derivatives and uses thereof
JP6380861B2 (ja) 2013-06-28 2018-08-29 ベイジーン リミテッド Ｒａｆキナ−ゼおよび／またはＲａｆキナ−ゼの二量体阻害剤としての縮合三環式ウレア系化合物
US9290519B2 (en) 2013-11-15 2016-03-22 Exxonmobil Chemical Patents Inc. Pyridyldiamido transition metal complexes, production and use thereof
EA039885B1 (ru) 2014-11-14 2022-03-23 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
WO2016138473A1 (en) 2015-02-26 2016-09-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
CN111440189B (zh) 2015-04-24 2022-08-09 广州再极医药科技有限公司 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用
US9890158B2 (en) 2015-10-09 2018-02-13 Abbvie S.Á.R.L. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
HRP20200133T1 (hr) 2016-01-22 2020-05-15 Janssen Pharmaceutica Nv Novi supstituirani derivati cijanoindolina kao inhibitori nik
CN107176951A (zh) 2016-03-11 2017-09-19 恩瑞生物医药科技（上海）有限公司 一种脲类化合物、其制备方法及其医药用途
US10167703B2 (en) 2016-03-31 2019-01-01 Saudi Arabian Oil Company Optimal well placement under constraints
US10561660B2 (en) 2016-06-21 2020-02-18 Nerviano Medical Sciences S.R.L. N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
EP3487503A1 (en) 2016-07-20 2019-05-29 GlaxoSmithKline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
EP3296297A1 (en) 2016-09-15 2018-03-21 Centre National De La Recherche Scientifique Benzimidazol derivatives for treating filovirus infection
EP3630778A1 (en) 2017-05-26 2020-04-08 Ichnos Sciences SA Novel inhibitors of map4k1
WO2018228920A1 (en) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
CA3074381A1 (en) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
BR112020008981A2 (pt) 2017-11-09 2020-11-17 Inflazome Limited novos compostos de sulfonamida carboxamida
CA3093469A1 (en) 2018-03-09 2019-09-12 The Brigham And Women's Hospital, Inc. Combination therapy for cardiovascular diseases
US11873303B2 (en) 2018-04-05 2024-01-16 Merck Patent Gmbh Substituted pyrazoles as type II IRAK inhibitors
KR20210030947A (ko) 2018-07-03 2021-03-18 노파르티스 아게 Nlrp3 길항제를 사용한 tnf 억제제 저항성 대상체를 위한 치료 방법 또는 치료제의 선택 방법
WO2020035495A1 (en) 2018-08-14 2020-02-20 Cynora Gmbh Organic molecules for optoelectronic devices
KR20210071976A (ko) 2018-09-04 2021-06-16 마젠타 테라퓨틱스 인코포레이티드 아릴 하이드로카본 수용체 길항제 및 사용 방법
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
EP3866789A4 (en) 2018-10-15 2022-07-06 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
EP3886852B1 (en) 2018-12-03 2024-01-31 Smilebiotek Zhuhai Limited Octyl gallate and esters thereof of for use in the treatment and prevention of age-related macular degeneration caused by bacillus megaterium
CA3124970A1 (en) 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2
EP3908274A1 (en) 2019-01-11 2021-11-17 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
ES3034157T3 (en) 2019-01-29 2025-08-13 Univ Degli Studi Di Salerno Modulators of potassium ion channels and uses thereof
CN111646995B (zh) * 2019-03-04 2023-03-21 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
US11559536B2 (en) 2019-05-20 2023-01-24 Duke University Compositions and methods for the treatment of inflammation in urological pathology
WO2021041975A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds
CA3151355C (en) 2019-09-26 2024-02-20 Yihan Wang Substituted aromatic fused ring derivative and composition comprising same, and use thereof
US20230140941A1 (en) 2020-03-13 2023-05-11 University Of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
WO2021188837A1 (en) 2020-03-20 2021-09-23 The Johns Hopkins University Prophylaxis and treatment of pathogenic coronavirus infections
US20230210853A1 (en) 2020-05-08 2023-07-06 Halia Therapeutics, Inc. Targeted nek7 inhibition for modulation of the nlrp3 inflammasome
DK4146348T3 (da) * 2020-05-08 2024-09-30 Halia Therapeutics Inc Inhibitorer af nek7-kinase
CA3185710A1 (en) 2020-06-02 2021-12-09 Chengdu Kanghong Pharmaceutical Co., Ltd. Novel thyroid hormone .beta. receptor agonist
KR20230035311A (ko) 2020-06-08 2023-03-13 할리아 테라퓨틱스, 인코포레이티드 Nek7 키나제의 억제제
GB202010464D0 (en) 2020-07-08 2020-08-19 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
US20230405008A1 (en) 2020-10-21 2023-12-21 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
WO2022159835A1 (en) 2021-01-25 2022-07-28 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022192944A1 (en) 2021-03-15 2022-09-22 Genieus Genomics Pty Ltd Combination therapy for treatment of als
MX2023011464A (es) 2021-04-05 2023-10-19 Halia Therapeutics Inc Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7).
WO2022226349A1 (en) 2021-04-22 2022-10-27 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
US20240336563A1 (en) 2021-04-26 2024-10-10 The Regents Of The University Of California G-alpha-s inhibitors and uses thereof
WO2022261352A1 (en) 2021-06-09 2022-12-15 Icahn School Of Medicine At Mount Sinai Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof
CN115616216B (zh) 2021-07-15 2025-08-12 华南理工大学 抑制或阻断faah与nlrp3之间相互作用的制剂的用途
CN117693340A (zh) 2021-07-23 2024-03-12 诺华股份有限公司 Nlrp3抑制剂治疗骨关节炎的给药方案
WO2023125935A1 (zh) 2021-12-31 2023-07-06 上海翰森生物医药科技有限公司 苯并哌啶衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
ZA202212146B (en) 2025-06-25
WO2021242505A1 (en) 2021-12-02
CN115843272B (zh) 2025-07-18
HRP20241304T1 (hr) 2024-12-06
US12091413B2 (en) 2024-09-17
LT4146348T (lt) 2024-10-10
RS65962B1 (sr) 2024-10-31
FI4146348T3 (fi) 2024-09-25
JP2023524597A (ja) 2023-06-12
JP7796671B2 (ja) 2026-01-09
CA3182276A1 (en) 2021-12-02
CN120699028A (zh) 2025-09-26
AU2021280893A1 (en) 2023-01-05
SI4146348T1 (sl) 2024-11-29
US20230416259A1 (en) 2023-12-28
PH12022553024A1 (en) 2024-05-20
EP4146348B1 (en) 2024-07-03
CN115843272A (zh) 2023-03-24
KR20230008763A (ko) 2023-01-16
US11161852B1 (en) 2021-11-02
DK4146348T3 (da) 2024-09-30
PL4146348T3 (pl) 2024-11-12
PT4146348T (pt) 2024-10-04
TW202208356A (zh) 2022-03-01
ES2991366T3 (es) 2024-12-03
HUE068185T2 (hu) 2024-12-28
US20220064173A1 (en) 2022-03-03
IL297979A (en) 2023-01-01
EP4146348A1 (en) 2023-03-15
US11713321B2 (en) 2023-08-01
US20210355130A1 (en) 2021-11-18
CO2022017622A2 (es) 2022-12-20
BR112022022669A2 (pt) 2023-01-17

Similar Documents

Publication Publication Date Title
MX2022013984A (es) Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
PH12023552774A1 (en) Nek7 inhibitors
MX2022015495A (es) Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7).
JOP20190229A1 (ar) مركبات تثبط بروتين mcl-1
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
ZA202400988B (en) Aak1 inhibitor and use thereof
PE20060075A1 (es) Composiciones farmaceuticas de alisciren
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
DOP2024000209A (es) Compuestos de heteroarilo para el tratamiento del dolor
UA116334C2 (uk) Тверді форми дозування бендамустину
CO2024015816A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2009007784A (es) Composiciones de tiacumicinas estables.
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
MY206262A (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2024013914A (es) Moduladores del inflamasoma nlrp3 y productos y metodos relacionados
EA202192322A1 (ru) Фармацевтические составы
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
CO2022003583A2 (es) Compuestos de curcumina y aminoácidos básicos
AR111760A1 (es) Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
BRPI1008000A2 (pt) composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto.
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors
MX2025011086A (es) Inhibidores de inflamasoma nlrp3 y usos de los mismos